https://www.selleckchem.com/pr....oducts/abemaciclib.h
We compared demographic, clinical, treatment, and outcome characteristics of facial cutaneous leishmaniasis (CL) and non-facial CL. In this retrospective cohort study, polymerase chain reaction confirmed Leishmania major CL patients with ≥2 documented hospital visits, 2014-2019, were included. Overall, 134 patients (34% and 66% with facial and non-facial CL, respectively) were included. Facial CL patients were younger (43% vs. 8% 18years, P0.001), with a higher proportion of females (41% vs. 25%, P=0.07) compared with non-fa